Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Karyn Pauze

Physician Assistant Altamont, NY Physician Assistant

NPI 1265610893 CMS profile 10561169

2508 Western Ave, Altamont, NY 12009

Open in the dashboard

General payments

$4,904

244 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karyn Pauze of Altamont, NY is reported in the CMS Open Payments database as having received $4,904 across 244 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,134 58
2024 General $2,039 102
2023 General $1,135 56
2022 General $543 25
2021 General $53 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karyn Pauze
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Karyn Pauze were reported at $1,134. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Karyn Pauze Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $53 $132 $37–$438 $132
2022 $543 $155 $48–$522 $149
2023 $1,135 $167 $52–$557 $160
2024 $2,039 $178 $55–$600 $164
2025 $1,134 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,204 75 payments
  2. Janssen Biotech, Inc. $607 25 payments
  3. Sun Pharmaceutical Industries Inc. $334 16 payments
  4. Genzyme Corporation $333 15 payments
  5. Lilly USA, LLC $266 13 payments
  6. Incyte Corporation $250 12 payments
  7. LEO Pharma Inc. $233 11 payments
  8. Novartis Pharmaceuticals Corporation $226 13 payments
  9. Regeneron Healthcare Solutions, Inc. $224 10 payments
  10. Pfizer Inc. $184 7 payments
  11. Other $1,044 47 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,728 241 payments
  2. Education $176 3 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $607 25 payments
  2. RINVOQ $571 31 payments
  3. DUPIXENT $475 22 payments
  4. SKYRIZI Immunology $372 30 payments
  5. OPZELURA $250 12 payments
  6. TALTZ $218 11 payments
  7. ADBRY $211 10 payments
  8. VTAMA $176 8 payments
  9. SKYRIZI Immunology $175 14 payments
  10. ILUMYA $166 8 payments
  11. Other $2,378 108 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

682

Median for Physician Assistant: 241

Drug cost

$726,785

Median for Physician Assistant: $4,110

Branded share of claims

17.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 25 $186,488
Dupixent Pen Dupilumab Brand 50 $185,271
Humira(Cf) Pen Adalimumab Brand 16 $181,520
Stelara Ustekinumab Brand 12 $158,355
Clobetasol Propionate Generic 81 $3,685
Metronidazole Generic 40 $3,375
Ketoconazole Generic 110 $2,675
Tretinoin Generic 16 $1,437
Triamcinolone Acetonide Generic 113 $1,256
Doxycycline Hyclate Generic 39 $626

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$62,731

Of which drugs: $2,202

Medicare patients

433

Average age 74

Services billed

1,942

259 women, 174 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 37%
Ischemic heart disease 27%
Diabetes 19%
Cancer 18%
Osteoporosis 18%
Chronic kidney disease 14%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 24 44 $25

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $348
$348 — —
SKYRIZI
  • AbbVie, Inc. $265
$265 — —
TREMFYA
  • Janssen Biotech, Inc. $173
$173 — —
OPZELURA
  • Incyte Corporation $172
$172 — —
DUPIXENT
  • GENZYME CORPORATION $107
  • Regeneron Healthcare Solutions, Inc. $44
$151 50 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

244 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record